Fusion Pharmaceuticals Inc (NAS:FUSN)
$ 21.55 0 (0%) Market Cap: 1.83 Bil Enterprise Value: 1.69 Bil PE Ratio: 0 PB Ratio: 7.56 GF Score: 38/100

Fusion Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 09, 2021 / 03:00PM GMT
Release Date Price: $9.23 (+2.10%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Thanks for joining us for the [next] session. I'm Matthew Harrison, one of the biotech analysts here. I'm very pleased to have John Valliant and John Crowley from Fusion with us to start the next session. Before we get started, I just need to read a quick disclaimer statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at [morganstanley.com/researchdisclosures]

And with that, I'm going to turn it over to John Valliant to make some opening comments, and then we'll jump into Q&A.

John F. Valliant
Fusion Pharmaceuticals Inc. - Founder, CEO & Director

Thanks, Matthew. I appreciate the opportunity to chat with everyone and to be here with our Chief Financial Officer, John Crowley. I'm John Valliant, CEO of Fusion Pharmaceuticals and excited to be part of this rapidly growing field of radiopharmaceuticals in oncology. Fusion really kicked off in around

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot